2013
Treatment strategies for peripheral T-cell lymphomas
Foss FM. Treatment strategies for peripheral T-cell lymphomas. Best Practice & Research Clinical Haematology 2013, 26: 43-56. PMID: 23768640, DOI: 10.1016/j.beha.2013.04.005.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAggressive first-line therapyAutologous stem cell transplantationConventional lymphoma therapyFirst-line therapyMajority of patientsStem cell transplantationSignal transduction inhibitorsHistone deacetylase inhibitorsFuture novel approachesLine therapyTransplant candidatesImproved survivalRelevant pathwaysAggressive diseaseCell transplantationInferior outcomesLymphoma therapyTransduction inhibitorsTreatment strategiesDeacetylase inhibitorsMonoclonal antibodiesMolecular profilingHeterogeneous group
2012
Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA. Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study. Clinical Lymphoma Myeloma & Leukemia 2012, 12: 238-243. PMID: 22542448, DOI: 10.1016/j.clml.2012.01.010.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalToxicity-related discontinuationProgression-free survivalIndependent central reviewMedian survivalInvestigator assessmentMycosis fungoidesCentral reviewMedian durationAggressive diseaseRetrospective analysisGrade 4 adverse eventsPrior systemic therapySubgroup efficacy analysesObjective response rateTransformed Mycosis FungoidesPROPEL StudyAdverse eventsObjective responseSystemic therapyCutaneous lesionsEfficacy analysisPoor prognosisTreatment optionsMedian number
2011
Peripheral T-cell lymphoma
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaStandard chemotherapeutic regimensBest treatment strategyMore effective therapiesHistone deacetylase inhibitorsWorld Health OrganizationAbundance of drugsAggressive diseaseChemotherapeutic regimensPoor outcomeTreatment optionsClinical trialsEffective therapyTreatment strategiesTherapeutic approachesPrognostic issuesDeacetylase inhibitorsLymphoma classificationMonoclonal antibodiesGene expression profilingHeterogeneous groupHealth OrganizationProteasome inhibitorsDisease biology
2010
Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances In Hematology And Oncology 2010, 8: 1-15. PMID: 21491667.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaPTCL subtypesTherapeutic regimensDisease state awarenessAggressive disease courseT-cell markersB-cell lymphomaMost patientsRefractory diseaseDisease courseIndolent courseAggressive diseaseLymphoproliferative disordersPoor prognosisTherapeutic overviewEffective treatmentProper diagnosisLymphomaRegimensSubtypesHeterogeneous groupPatientsPrognosisDisease
2007
Efficacy of Denileukin Diftitox in Subcutaneous Panniculitis-Like T-Cell Lymphoma
Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of Denileukin Diftitox in Subcutaneous Panniculitis-Like T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2007, 7: 541-545. PMID: 18021473, DOI: 10.3816/clm.2007.n.040.Peer-Reviewed Original ResearchConceptsT-cell phenotypeDenileukin diftitoxSubcutaneous panniculitis-like T-cell lymphomaPanniculitis-like T-cell lymphomaSubcutaneous panniculitis-like lymphomaSystemic multi-agent chemotherapyAddition of bexaroteneMedian response durationMulti-agent chemotherapyComplete clinical regressionBone marrow transplantationT-cell lymphomaPleomorphic lymphocytesImmunosuppressive therapyRefractory patientsClinical regressionClinical responseMost patientsMarrow transplantationAggressive diseasePrognostic significanceDisease progressionRadiation therapyTraditional therapiesResponse duration